{
  "abstract": "Relevance: Despite the introduction of highly effective treatment methods such as brentuximab vedotin and checkpoint inhibitors (nivolumab, pembrolizumab), stem cell transplantation remains relevant for patients with relapse/refractory Hodgkin's lymphoma. For such patients the probability of recovery after autoSCT is up to 60%, this indicator can be increased by using brentuximab vedotin or checkpoint inhibitors as consolidating or maintenance therapy. Materials and methods: From 2015 to 2025, 90 patients with Hodgkin's lymphoma underwent autoSCT in at the Moscow Clinical Science and Research Center 52: 46 (51%) men, 44 (49%) women, the median age was 32 years (19-58 years). According to the Ann Arbor staging, 3 patients (3%) had stage I, 34 (38%) - II, 22 (24%) - III, 31 (34%) - IV. The median number of therapy lines before autoSCT is 3 (2-8). The majority of patients had a complete metabolic response before autoSCT - 56 patients (83%), 7 (12%) achieved a partial report, 2 (5%) - stabilization. The pretransplant conditioning regimens were BEAM - 13 pts (15%), BeEAM - 75 pts (83%), CEAM – 2 pts (2%). The median number of transfused PBSCs is 6.25*10^6 CD34+cells (1.4 – 25.5). After autoSCT 34 patients (38%) received maintenance therapy with brentuximab vedotin (29 patients – 32%), nivolumab or pembrolizumab (4 patients – 4.4%) or a combination of BV+nivo (2 pts – 2%). Results: The median follow–up was 35 months (0-109). The median of leukocyte engraftment was 13 (8-31) days (18 for BEAM and 12 days for BeEAM). Infectious complications were represented by mucositis 3-4 grade (31% for BEAM vs 35% for BeEAM), bacteremia (15% for BEAM vs 23% for BeEAM), pneumonia (15% for BEAM vs 12% for BeEAM), clostridial colitis (23% for BEAM vs 16% for BeEAM), invasive aspergillosis (undetected on BEAM and 9% for BeEAM), invasive candidiasis (8% for BEAM vs 3% for BeEAM), reactivation of herpesvirus infections (31% for BEAM vs 28% for BeEAM). Transplant- related mortality was 4.4% (4 patients), the causes of mortality were infectious complications (3 patients - sepsis, 1 patient was CMV infection and secondary hemophagocytic syndrome). The 3-year overall survival (OS) was 88%, and the progressive–free survival (PFS) 80%. There were no significant differences in OS and PFS depending on the Ann-Arbor stage, the number of previous lines of therapy, the response to autoSCT, and the conditioning regimen, but the effect of maintenance therapy on OS and PFS was revealed: 3-year OS and PFS in the group of patients receiving maintenance therapy were 95% and 90%, in the group without maintenance therapy 84% (p=0.053) and 74% (p=0.058) accordingly. The use of checkpoint inhibitors showed advantages in OS and PFS in comparison with brentuximab-vedotin (OS 100% vs. 94%, PFS 100% vs. 87%), but the differences are not significant. Conclusion and conclusions: Despite highly effective first line treatment programs for the Hodgkin's lymphoma, autoSCT remains an effective method of consolidation for patients with R/R disease. Сonsidering the toxicity of conditioning regimes and the significant cure of this category of patients, effective methods of infection prevention in the early post-transplant period are necessary. Maintenance therapy with checkpoint inhibitors and/or brentuximab vedotin after autoSCT can significantly reduce the risk of relaps.",
  "abstract_shown": true,
  "affiliations": [
    "Moscow Clinical Science and Research Center 52, Russia"
  ],
  "article_type": null,
  "arxiv": null,
  "author_total": 5,
  "authors": [
    {
      "affs": [
        0
      ],
      "name": "Ekaterina KARIMOVA"
    },
    {
      "affs": [
        0
      ],
      "name": "Eugenia ZHELNOVA"
    },
    {
      "affs": [
        0
      ],
      "name": "Leonid KHORDZHASOV"
    },
    {
      "affs": [
        0
      ],
      "name": "Ekaterina GRISHINA"
    },
    {
      "affs": [
        0
      ],
      "name": "Maryana LYSENKO"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/e70cg1ywhpjm1.bib",
  "cited_by": 0,
  "doi": "10.1016/j.htct.2026.107705",
  "fulltext_url": "http://www.sciencedirect.com/science/article/pii/S2531137926014525",
  "id": "e70cg1ywhpjm1",
  "issns": [
    "2531-1379",
    "2531-1387"
  ],
  "landing_url": "https://doi.org/10.1016/j.htct.2026.107705",
  "language": "en",
  "licence": "CC-BY",
  "licence_label": "CC BY",
  "licence_source": "journal",
  "licence_url": "https://creativecommons.org/licenses/by/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "lcc",
      "RC633-647.5"
    ],
    [
      "openalex",
      "2734|Lymphoma Diagnosis and Treatment"
    ]
  ],
  "openalex": "W7223557086",
  "pdf_url": null,
  "pmcid": null,
  "pmid": null,
  "published": "2026-10-23",
  "publisher": "Elsevier",
  "ris": "https://research.draconitic.com/paper/e70cg1ywhpjm1.ris",
  "sources": [
    {
      "first_seen": "2026-10-30T13:43:32Z",
      "native_id": "59d73a214c2d4b9392581b496f77c259",
      "source": "doaj",
      "url": "https://doi.org/10.1016/j.htct.2026.107705"
    }
  ],
  "subjects": [
    {
      "field": "medicine",
      "origin": "lcc:RC633-647.5",
      "subfield": "endocrinology-metabolism"
    }
  ],
  "title": "EFFICACY AND SAFETY OF HIGH-DOSE CONSOLIDATION WITH AUTOLOGOUS BLOOD STEM CELL SUPPORT IN PATIENTS WITH HODGKIN`S LYMPHOMA: 10 YEARS OF EXPERIENCE IN ONE HOSPITAL",
  "title_text": "EFFICACY AND SAFETY OF HIGH-DOSE CONSOLIDATION WITH AUTOLOGOUS BLOOD STEM CELL SUPPORT IN PATIENTS WITH HODGKIN`S LYMPHOMA: 10 YEARS OF EXPERIENCE IN ONE HOSPITAL",
  "type": "peer-reviewed",
  "updated_at": "2026-10-30T13:43:32Z",
  "url": "https://research.draconitic.com/paper/e70cg1ywhpjm1",
  "venue": "Hematology, Transfusion and Cell Therapy",
  "versions": []
}